Merck Receives European Approval for ELONVA (corifollitropin alfa injection) (pharmanews.eu, 15 February 2010)

15 Feb 2010

Following the Engage trial - the largest double-blind fertility agent trial performed to date - Merck & Co. Inc. announced European Commission approval for ELONVA, indicated for controlled ovarian stimulation in combination with a GnRH antagonist, in assisted reproductive technology (ART) programmes.